WALTHAM, Mass.--(BUSINESS WIRE)--Glytec today announces notices of allowance received from the United States Patent and Trademark Office (USPTO) for three patent applications directed toward its eGlycemic Management System®, or eGMS®.
The company is aggressively building a patent portfolio that affords protection of its proprietary diabetes technologies. The three new allowances will issue as patents over the next 60 days -- adding to U.S. Patent 9,233,204 and U.S. Patent 9,171,343 -- bringing the total number of patents held by Glytec to five. The company has more than 30 other U.S. and international patent applications pending.
“These additional patents reflect another important set of breakthrough advancements made over the company’s now 11-year history, contributing to more effective care for people living with diabetes,” says Robby Booth, Glytec’s Senior Vice President Research & Development. “While we’re pleased and proud to be receiving additional patent protection for a broad array of methods and systems, the unprecedented clinical results our clients are achieving stand as the greatest testimony to the uniqueness of Glytec’s eGMS®.”
The three allowed applications that will soon issue as patents recite, among other things, methods and systems to:
Control blood glucose levels among inpatient and
outpatient populations across care settings. This includes: (a)
intravenous insulin therapy and transitions to subcutaneous basal or
basal-bolus insulin therapy, and (b) the integration of connected
devices such as blood glucose meters, insulin pens and infusion pumps.
Utilize smartphone-based interactivity between
and on behalf of patients and providers. This includes: (a)
prescriber-initiated communication regarding medication adjustments,
(b) alerting of healthcare professionals to out-of-range glycemic
measurements, (c) database-driven dietary and carbohydrate
recommendations, and (d) management of events that affect blood
glucose, such as exercise, travel, changes in circadian rhythms, and
- Mitigate diabetes-related and stress-induced hyperglycemia in hospitalized patients. This includes calculations and recommendations for: (a) optimal insulin infusion rates, (b) appropriate time intervals between blood glucose readings, (c) continuous nutritional insulin infusion, and (d) transitions from intravenous insulin therapy to subcutaneous basal or basal-bolus insulin therapy.
Glytec offers the only patented and FDA-cleared solution for glycemic management that encompasses insulin dosing decision support for: (1) inpatient AND outpatient settings, (2) intravenous AND subcutaneous insulin therapies, (3) adult AND pediatric populations, and (4) patients with AND without diabetes.
Andrew S. Rhinehart, MD, FACP, FACE, CDE, BC-ADM, CDTC, Glytec’s Chief Medical Officer, explains, “For inpatient populations, our eGMS® translates to significant reductions in infections, adverse drug events and other complications, and in turn, significant reductions in length of stay and readmission rates. For outpatient populations, our eGMS® is supporting substantial reductions in A1c levels, which for patients with diabetes is the primary indicator of control and costs, both personal and financial.”
As a leading innovator in the care of patients with diabetes, Glytec is pioneering the way hospitals and health systems use technology to ensure optimal glucose control and prevent the associated frequency, risks and costs of hyperglycemia and hypoglycemia. The company, founded in 2006, has developed a comprehensive eGlycemic Management System®, or eGMS®, which centers on the only FDA-cleared solution for insulin dosing able to support personalized intravenous and subcutaneous therapy for adult and pediatric populations across the entire care continuum. The solution seamlessly integrates with EMR systems for streamlined use in all inpatient and outpatient settings. It also integrates with connected devices for at-home care managed through telehealth, population health and other value-based programs. The eGMS® employs a cloud-hosted software-as-a-service (SaaS) delivery model, allowing for rapid implementation and anytime/anywhere access. The efficacy of the eGMS®, including its ability to substantively improve clinical and financial outcomes, has been validated by more than 55 published studies. Results have included dramatic reductions in lengths of stay, readmissions and A1c levels. The company has offices in Waltham, Massachusetts and Greenville, South Carolina. For more information, visit www.glytecsystems.com.